Armata Pharmaceuticals, Inc. (ARMP)
USD 1.13
(-9.6%)
USD 1.13
(-9.6%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 142.02 Million USD | 137.69% |
| 2022 | 59.75 Million USD | 34.67% |
| 2021 | 44.37 Million USD | 114.78% |
| 2020 | 20.65 Million USD | 90.27% |
| 2019 | 10.85 Million USD | 218.14% |
| 2018 | 3.41 Million USD | 0.18% |
| 2017 | 3.4 Million USD | -59.79% |
| 2016 | 8.47 Million USD | -54.89% |
| 2015 | 18.77 Million USD | -25.42% |
| 2014 | 25.18 Million USD | -51.73% |
| 2013 | 52.16 Million USD | 471.52% |
| 2012 | 9.12 Million USD | 0.0% |
| 2008 | 10.92 Million USD | -10.72% |
| 2007 | 12.23 Million USD | 1.11% |
| 2006 | 12.1 Million USD | -33.61% |
| 2005 | 18.22 Million USD | -9.78% |
| 2004 | 20.2 Million USD | -13.82% |
| 2003 | 23.44 Million USD | -49.11% |
| 2002 | 46.06 Million USD | 36.95% |
| 2001 | 33.63 Million USD | 37.06% |
| 2000 | 24.54 Million USD | 266.31% |
| 1999 | 6.7 Million USD | 59.52% |
| 1998 | 4.2 Million USD | 0.0% |
| 1997 | 4.2 Million USD | -25.0% |
| 1996 | 5.6 Million USD | 33.33% |
| 1995 | 4.2 Million USD | 10.53% |
| 1994 | 3.8 Million USD | 100.0% |
| 1993 | 1.9 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 154.41 Million USD | -12.69% |
| 2024 Q1 | 176.86 Million USD | 24.53% |
| 2023 Q4 | 142.02 Million USD | 13.49% |
| 2023 FY | 142.02 Million USD | 137.69% |
| 2023 Q2 | 82.06 Million USD | -4.94% |
| 2023 Q3 | 125.14 Million USD | 52.49% |
| 2023 Q1 | 86.33 Million USD | 44.48% |
| 2022 Q4 | 59.75 Million USD | 26.32% |
| 2022 Q2 | 47.69 Million USD | 3.17% |
| 2022 FY | 59.75 Million USD | 34.67% |
| 2022 Q1 | 46.22 Million USD | 4.18% |
| 2022 Q3 | 47.3 Million USD | -0.82% |
| 2021 Q3 | 18.91 Million USD | -3.79% |
| 2021 FY | 44.37 Million USD | 114.78% |
| 2021 Q2 | 19.66 Million USD | 4.4% |
| 2021 Q1 | 18.83 Million USD | -8.84% |
| 2021 Q4 | 44.37 Million USD | 134.57% |
| 2020 Q4 | 20.65 Million USD | -1.89% |
| 2020 Q2 | 19.82 Million USD | 86.66% |
| 2020 Q3 | 21.05 Million USD | 6.22% |
| 2020 Q1 | 10.62 Million USD | -2.19% |
| 2020 FY | 20.65 Million USD | 90.27% |
| 2019 Q4 | 10.85 Million USD | -2.81% |
| 2019 Q3 | 11.17 Million USD | -9.07% |
| 2019 Q2 | 12.28 Million USD | 163.87% |
| 2019 Q1 | 4.65 Million USD | 36.42% |
| 2019 FY | 10.85 Million USD | 218.14% |
| 2018 Q4 | 3.41 Million USD | -9.37% |
| 2018 Q1 | 3.1 Million USD | -8.75% |
| 2018 Q2 | 3.38 Million USD | 8.75% |
| 2018 FY | 3.41 Million USD | 0.18% |
| 2018 Q3 | 3.76 Million USD | 11.39% |
| 2017 Q3 | 4.02 Million USD | -23.28% |
| 2017 Q2 | 5.24 Million USD | -31.47% |
| 2017 FY | 3.4 Million USD | -59.79% |
| 2017 Q4 | 3.4 Million USD | -15.33% |
| 2017 Q1 | 7.65 Million USD | -9.66% |
| 2016 Q1 | 19.36 Million USD | 3.12% |
| 2016 Q2 | 7.79 Million USD | -59.74% |
| 2016 Q3 | 7.8 Million USD | 0.17% |
| 2016 Q4 | 8.47 Million USD | 8.5% |
| 2016 FY | 8.47 Million USD | -54.89% |
| 2015 Q3 | 18.41 Million USD | -20.91% |
| 2015 FY | 18.77 Million USD | -25.42% |
| 2015 Q4 | 18.77 Million USD | 1.98% |
| 2015 Q2 | 23.28 Million USD | -44.14% |
| 2015 Q1 | 41.68 Million USD | 65.53% |
| 2014 Q1 | 58.45 Million USD | 12.06% |
| 2014 Q2 | 40.28 Million USD | -31.09% |
| 2014 Q3 | 17.08 Million USD | -57.6% |
| 2014 FY | 25.18 Million USD | -51.73% |
| 2014 Q4 | 25.18 Million USD | 47.42% |
| 2013 Q4 | 52.16 Million USD | 0.0% |
| 2013 FY | 52.16 Million USD | 471.52% |
| 2012 FY | 9.12 Million USD | 0.0% |
| 2009 Q3 | 1.79 Million USD | -14.39% |
| 2009 Q2 | 2.09 Million USD | -80.7% |
| 2009 Q1 | 10.87 Million USD | -0.43% |
| 2008 FY | 10.92 Million USD | -10.72% |
| 2008 Q1 | 11.22 Million USD | -8.23% |
| 2008 Q2 | 13.24 Million USD | 18.0% |
| 2008 Q3 | 12.24 Million USD | -7.59% |
| 2008 Q4 | 10.92 Million USD | -10.79% |
| 2007 Q1 | 11.77 Million USD | -2.67% |
| 2007 FY | 12.23 Million USD | 1.11% |
| 2007 Q2 | 13.69 Million USD | 16.29% |
| 2007 Q4 | 12.23 Million USD | 14.98% |
| 2007 Q3 | 10.64 Million USD | -22.31% |
| 2006 FY | 12.1 Million USD | -33.61% |
| 2006 Q1 | 19.17 Million USD | 5.2% |
| 2006 Q2 | 18.6 Million USD | -2.98% |
| 2006 Q4 | 12.1 Million USD | -34.46% |
| 2006 Q3 | 18.46 Million USD | -0.76% |
| 2005 Q4 | 18.22 Million USD | -0.12% |
| 2005 FY | 18.22 Million USD | -9.78% |
| 2005 Q3 | 18.24 Million USD | -11.28% |
| 2005 Q1 | 20.31 Million USD | 0.55% |
| 2005 Q2 | 20.56 Million USD | 1.25% |
| 2004 Q1 | 23.93 Million USD | 2.09% |
| 2004 Q2 | 24.55 Million USD | 2.62% |
| 2004 Q3 | 21.38 Million USD | -12.94% |
| 2004 Q4 | 20.2 Million USD | -5.51% |
| 2004 FY | 20.2 Million USD | -13.82% |
| 2003 Q1 | 44.8 Million USD | -2.73% |
| 2003 Q4 | 23.44 Million USD | 4.21% |
| 2003 Q2 | 35.23 Million USD | -21.37% |
| 2003 Q3 | 22.49 Million USD | -36.15% |
| 2003 FY | 23.44 Million USD | -49.11% |
| 2002 Q1 | 31.06 Million USD | -7.65% |
| 2002 FY | 46.06 Million USD | 36.95% |
| 2002 Q2 | 50.01 Million USD | 61.0% |
| 2002 Q4 | 46.06 Million USD | -3.57% |
| 2002 Q3 | 47.77 Million USD | -4.48% |
| 2001 Q1 | 23.82 Million USD | -2.93% |
| 2001 Q4 | 33.63 Million USD | 19.66% |
| 2001 Q3 | 28.1 Million USD | 34.31% |
| 2001 Q2 | 20.92 Million USD | -12.15% |
| 2001 FY | 33.63 Million USD | 37.06% |
| 2000 Q2 | 6.74 Million USD | 7.08% |
| 2000 Q3 | 12.41 Million USD | 84.09% |
| 2000 Q4 | 24.54 Million USD | 97.64% |
| 2000 FY | 24.54 Million USD | 266.31% |
| 2000 Q1 | 6.29 Million USD | -5.98% |
| 1999 Q2 | 4.4 Million USD | 12.82% |
| 1999 FY | 6.7 Million USD | 59.52% |
| 1999 Q4 | 6.7 Million USD | 55.81% |
| 1999 Q1 | 3.9 Million USD | -7.14% |
| 1999 Q3 | 4.3 Million USD | -2.27% |
| 1998 Q1 | 4.9 Million USD | 16.67% |
| 1998 Q2 | 4.4 Million USD | -10.2% |
| 1998 Q3 | 4.1 Million USD | -6.82% |
| 1998 Q4 | 4.2 Million USD | 2.44% |
| 1998 FY | 4.2 Million USD | 0.0% |
| 1997 FY | 4.2 Million USD | -25.0% |
| 1997 Q1 | 4.9 Million USD | -12.5% |
| 1997 Q2 | 4.8 Million USD | -2.04% |
| 1997 Q3 | 4.5 Million USD | -6.25% |
| 1997 Q4 | 4.2 Million USD | -6.67% |
| 1996 Q1 | 4.3 Million USD | 2.38% |
| 1996 FY | 5.6 Million USD | 33.33% |
| 1996 Q4 | 5.6 Million USD | 9.8% |
| 1996 Q2 | 6.2 Million USD | 44.19% |
| 1996 Q3 | 5.1 Million USD | -17.74% |
| 1995 Q4 | 4.2 Million USD | 27.27% |
| 1995 FY | 4.2 Million USD | 10.53% |
| 1995 Q3 | 3.3 Million USD | -5.71% |
| 1995 Q1 | 3.7 Million USD | -2.63% |
| 1995 Q2 | 3.5 Million USD | -5.41% |
| 1994 FY | 3.8 Million USD | 100.0% |
| 1994 Q4 | 3.8 Million USD | 22.58% |
| 1994 Q2 | 3.2 Million USD | 0.0% |
| 1994 Q3 | 3.1 Million USD | -3.13% |
| 1993 FY | 1.9 Million USD | 0.0% |
| 1993 Q4 | 1.9 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 9.14 Million USD | -1452.739% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -5877.652% |
| Actinium Pharmaceuticals, Inc. | 45.06 Million USD | -215.158% |
| Azitra, Inc. | 2.2 Million USD | -6349.004% |
| Can-Fite BioPharma Ltd. | 3.74 Million USD | -3691.484% |
| Chromocell Therapeutics Corporation | 6.54 Million USD | -2071.384% |
| Calidi Biotherapeutics, Inc. | 18.25 Million USD | -678.071% |
| CEL-SCI Corporation | 17.31 Million USD | -720.343% |
| iBio, Inc. | 7.41 Million USD | -1816.721% |
| Lineage Cell Therapeutics, Inc. | 38.99 Million USD | -264.214% |
| MAIA Biotechnology, Inc. | 7.08 Million USD | -1903.416% |
| Matinas BioPharma Holdings, Inc. | 46.33 Million USD | -206.546% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | -1034.878% |
| NovaBay Pharmaceuticals, Inc. | 5.72 Million USD | -2383.024% |
| NanoViricides, Inc. | 1.35 Million USD | -10352.716% |
| Oragenics, Inc. | 1.79 Million USD | -7798.482% |
| BiomX Inc. | 55.07 Million USD | -157.883% |
| BiomX Inc. | 55.07 Million USD | -157.883% |
| Protalix BioTherapeutics, Inc. | 50.86 Million USD | -179.227% |
| Palatin Technologies, Inc. | 10.85 Million USD | -1208.569% |
| Scorpius Holdings, Inc. | 22.74 Million USD | -524.487% |
| Theriva Biologics, Inc. | 20.51 Million USD | -592.352% |